基本信息
文件名称：2017-日本hepa治疗HCC-ctace和Hepa的对比-无明显差异.pdf
文件大小：488.66 KB
总页数：8 页
更新时间：2018-10-24
总字数：约5.09万字
文档摘要
a Springer Science+Business Media New York 2016 Abdom Radiol (2017) 42:612–619 Abdominal Published online: 13 September 2016 DOI: 10.1007/s00261-016-0900-y Radiology Short-term ef?cacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization Manabu Morimoto, Satoshi Kobayashi, Satoshi Moriya, Makoto Ueno, Shun Tezuka, Kuniyasu Irie, Yoshihiro Goda, Shinichi Ohkawa Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan Abstract rates and the median survival time of the patients treated with TACE with SAP and with conventional TACE were Purpose: This study aimed to compare the short-term 76% and 74%, and 18 months and 21 months, respectively. efficacy of transarterial chemoembolization (TACE) Overall survival was related to the short-term response. An with epirubicin-loaded superabsorbent polymer embolics alpha-fetoprotein level 1,000 ng/mL was a significant (SAP) and conventional TACE in TACE-na?ve patients¨ short-term response marker on multivariate analysis. with unresectable hepatocellular carcinoma (HCC). Conclusions: For TACE-na?ve patients, TACE with SAP¨ Methods: Fifty consecutive patients (mean age, 72.8 years; and conventional TACE had comparable safety and short- hepatitis C, 46%; BCLC-A or B, 52% or 48%) treated with term efficacies. TACE with SAP during 2013–2015 and 55 consecutive patients (mean age, 71.8 years; hepatitis C, 40%; BCLC-A Key words: TACE—Beads—Embolization— or B, 51% or 49%) treated with conventional TAC
a Springer Science+Business Media New York 2016 Abdom Radiol (2017) 42:612–619 Abdominal Published online: 13 September 2016 DOI: 10.1007/s00261-016-0900-y Radiology Short-term ef?cacy of transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for hepatocellular carcinoma: comparison with conventional transarterial chemoembolization Manabu Morimoto, Satoshi Kobayashi, Satoshi Moriya, Makoto Ueno, Shun Tezuka, Kuniyasu Irie, Yoshihiro Goda, Shinichi Ohkawa Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan Abstract rates and the median survival time of the patients treated with TACE with SAP and with conventional TACE were Purpose: This study aimed to compare the short-term 76% and 74%, and 18 months and 21 months, respectively. efficacy of transarterial chemoembolization (TACE) Overall survival was related to the short-term response. An with epirubicin-loaded superabsorbent polymer embolics alpha-fetoprotein level 1,000 ng/mL was a significant (SAP) and conventional TACE in TACE-na?ve patients¨ short-term response marker on multivariate analysis. with unresectable hepatocellular carcinoma (HCC). Conclusions: For TACE-na?ve patients, TACE with SAP¨ Methods: Fifty consecutive patients (mean age, 72.8 years; and conventional TACE had comparable safety and short- hepatitis C, 46%; BCLC-A or B, 52% or 48%) treated with term efficacies. TACE with SAP during 2013–2015 and 55 consecutive patients (mean age, 71.8 years; hepatitis C, 40%; BCLC-A Key words: TACE—Beads—Embolization— or B, 51% or 49%) treated with conventional TAC